ArticleJournal of the American Chemical Society2026
Spontaneous Intracellular Formation of Covalent Organic Frameworks via Enzyme-Initiated Cascade Reactions to Boost Cancer Radiotherapy.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor radioresistance is a leading cause of radiotherapy failure. This study presents a facile strategy for enhancing tumor radiosensitivity using a covalent organic framework (COF) constructed within cells. Upon cellular internalization, acetamide and iodoacetal precursors undergo hydrolysis to form amine and iodoaldehyde monomers that spontaneously polymerize and crystallize within the lysosomes. This intracellularly generated iodine-rich COF (in situ UM-113) possesses an ordered structure that effectively facilitates radiation energy deposition, producing localized reactive oxygen species and amplifying DNA damage. In vitro and in vivo, in situ UM-113 suppresses tumor growth by triggering both ferroptosis and mitotic catastrophe. This strategy bypasses the complex synthesis and purification steps required for conventional nanomedicine. Thus, in situ COF construction is a promising strategy for enhancing cancer radiotherapy, offering a modular platform for the intracellular synthesis of functional bionanomaterials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.